UBS AM
TMCI icon

UBS AM’s Treace Medical Concepts TMCI Stock Holding History

UBS AM’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-126,761
Closed -$735K – 2756
2024
Q3 		$735K Sell
126,761
-6,108
-5% -$39.2K ﹤0.01% 2522
2024
Q2 		$884K Buy
132,869
+96,992
+270% +$784K ﹤0.01% 2438
2024
Q1 		$468K Sell
35,877
-700
-2% -$9.33K ﹤0.01% 2306
2023
Q4 		$466K Sell
36,577
-417,105
-92% -$4.21M ﹤0.01% 2340
2023
Q3 		$5.95M Buy
453,682
+11,329
+3% +$207K ﹤0.01% 1148
2023
Q2 		$11.1M Hold
442,353
– – 0.01% 931
2023
Q1 		$11.1M Buy
442,353
+425,296
+2,493% +$9.99M 0.01% 931
2022
Q4 		$392K Buy
+17,057
New +$393K ﹤0.01% 2266

Other funds holding TMCI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

UBS AM's TMCI Position: Q4 2024 in Review

UBS AM sold out of Treace Medical Concepts (TMCI) in Q4 2024, closing a stake of 126,761 shares — an estimated $735K sold.

UBS AM first reported a position in TMCI in Q4 2022 and held it in 8 quarters. The position peaked at $11.1M in Q2 2023. 135 funds tracked by Wall St. Rank hold TMCI as of Q4 2024.

  • UBS AM reported no remaining Treace Medical Concepts position as of Q4 2024 after selling out during the quarter.
  • UBS AM sold 126,761 Treace Medical Concepts shares in Q4 2024, an estimated $735K.
  • UBS AM first reported a position in Treace Medical Concepts in Q4 2022 and held it in 8 quarters.
  • UBS AM's Treace Medical Concepts position peaked at $11.1M in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q4 2024.

Based on UBS AM's 13F filing for Q4 2024, filed 14 Feb 2025.